Login
SubscribeBioTime
Geron hESC Trial to Resume?
Jef Akst | May 27, 2014 | 1 min read
Nearly three years after Geron shuttered its stem cell program, BioTime receives funding to relaunch a Phase 1 trial for spinal cord injury.
Geron Sells Stem Cell Assets
Beth Marie Mole | Jan 8, 2013 | 2 min read
BioTime finalizes a deal to buy Geron’s defunct human embryonic stem cell assets.